GLC Biotechnology, Inc.
TEE (Toehold-Enrichment-Extraction) technology – a novel DNA extraction method that selectively enriches mutated DNA while preserving sequence integrity, enabling highly sensitive mutation detection i
- Sector
- Medtech
- Total capital
- $3.9M
- Federal grants
- $3.9M
- 6 awards · 2016–2024
- Rank in peer group#50 of 112
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 8 pending
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · Development of An Innovative TEE Technology for Mutation Detection$928K
- Federal grantHealth and Human S · Phase II · Development of An Innovative TEE Technology for Mutation Detection$1.1M
- Federal grantHealth and Human S · Phase II · A Novel Method for Efficiently and Robustly Retrieving Circulating miRNAs$750K
- Federal grantHealth and Human S · Phase II · A Novel Method for Efficiently and Robustly Retrieving Circulating miRNAs$750K
- Federal grantHealth and Human S · Phase I · Development of a novel liquid biopsy test to assist targeted MSI-H cancer treatment$225K
- Federal grantHealth and Human S · Phase I · A Method for Quantitatively Retrieving Circulating miRNAs from Plasma$225K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 112 peers
Line = medianMedtech · Instrument
- Federal grants#50 · top 45%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 0 granted of 8- PendingNucleic Acid Probe Compositions For Enriching, Extracting, And/or Detecting A Variant Target Nucleic Acid In A SampleUSPTOApplication 18995622
- PendingMethods And Materials For Quantification Of Fusobacterium Nucleatum Dna In Stool To Diagnose Colorectal NeoplasmUSPTOApplication 13947044
- PendingStool Collection Methods For Analysis Of Dna In StoolUSPTOApplication 13745947
Show all 8 patent records
- Nucleic Acid Probe Compositions For Enriching, Extracting, And/or Detecting A Variant Target Nucleic Acid In A SampleJun 18, 2026 · Application 18995622Pending
- Methods And Materials For Quantification Of Fusobacterium Nucleatum Dna In Stool To Diagnose Colorectal NeoplasmJan 23, 2014 · Application 13947044Pending
- Stool Collection Methods For Analysis Of Dna In StoolSep 19, 2013 · Application 13745947Pending
- Method For Automated Capture And Purification Of Multiple Nucleic Acid Targets From Stool SamplesApplication 62030027Pending
- Method and materials to remove impurities from stool to facilitate nucleic acids capture and purificationApplication 61994975Pending
- Method and materials to deplete and block inhibitors and impurities in stool for nucleic acids capture and purificationApplication 61994977Pending
- Nucleic Acid Probe Compositions For Enriching, Extracting, And/or Detecting A Variant Target Nucleic Acid In A SampleApplication 63371557Pending
- Nucleic Acid Probe Compositions For Enriching, Extracting, And/or Detecting A Variant Target Nucleic Acid In A SampleApplication PCTUS2023072192Pending
Related companies, and why
- CEREUS DIAGNOSTICS CORP.Similar federal contract value in Medtech · null in contracts
- FLAT EARTH, INC.Similar federal contract value in Medtech · null in contracts
- Convergent Genomics, Inc.Similar federal contract value in Medtech · null in contracts
- OPTIMAL MOBILITY INCSimilar federal contract value in Medtech · null in contracts
- ROM Technologies, Inc.Similar federal contract value in Medtech · null in contracts
- NOVION TECHNOLOGIES, INC.Similar federal contract value in Medtech · null in contracts
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .